AI Article Synopsis
- The rising threat of smallpox bioterrorism and concerns over side effects from current live-virus vaccines highlight the need for new vaccines with improved efficacy.
- This study focused on using DNA vaccines with specific antigen-encoding plasmids, which can reduce risks associated with traditional live-virus vaccines.
- Findings showed that adding B-type CpG oligodeoxynucleotides (ODNs) as TLR9 ligands enhanced the immune response and protective effects of the L1R DNA vaccine against Orthopoxvirus in mice, making it a promising method for smallpox immunization.
Article Abstract
Potential threat of smallpox bioterrorism and concerns related to the adverse effects of currently licensed live-virus vaccines suggest the need to develop novel vaccines with better efficacy against smallpox. Use of DNA vaccines containing specific antigen-encoding plasmids prevents the risks associated with live-virus vaccines, offering a promising alternative to conventional smallpox vaccines. In this study, we investigated the efficiency of toll-like receptor (TLR) ligands in enhancing the immunogenicity of smallpox DNA vaccines. BALB/c mice were immunized with a DNA vaccine encoding the vaccinia virus L1R protein, along with the cytosine-phosphate-guanine (CpG) motif as a vaccine adjuvant, and their immune response was analyzed. Administration of B-type CpG oligodeoxynucleotides (ODNs) as TLR9 ligands 24 h after DNA vaccination enhanced the Th2-biased L1R-specific antibody immunity in mice. Moreover, B-type CpG ODNs improved the protective effects of the DNA vaccine against the lethal Orthopoxvirus challenge. Therefore, use of L1R DNA vaccines with CpG ODNs as adjuvants is a promising approach to achieve effective immunogenicity against smallpox infection.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s12033-023-00800-4 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Preclinical study of TLR stimulation combined PD-1 antibody enhance the therapeutic effect of microwave ablation on NSCLC.
Clin Transl Oncol
December 2024
Hebei Key Laboratory of Respiratory Critical Care Medicine, The First Department of Pulmonary and Critical Care Medicine, The Second Hospital of Hebei Medical University, Hebei Institute of Respiratory Diseases, No. 215 Heping West Road, Shijiazhuang, 050000, Hebei, China.
Purpose: The purpose of this study was to investigate the therapeutic efficacy of the combination of microwave ablation (MWA) with immune checkpoints blockade and TLR9 stimulation in the treatment of non-small cell lung cancer (NSCLC) using the C57BL/6 tumor-bearing mice model.
Materials And Methods: Tumor-bearing mice were treated with MWA, programmed cell death protein1 blockade (PD-1) plus MWA (MWA + P), TLR9 agonist CpG ODNs and MWA (MWA + C), PD-1 blockade and CpG ODNs (P + C), MWA plus PD-1 blockade and CpG ODNs (MWA + P + C), or untreated. Survival time was evaluated with the Kaplan-Meyer method comparing survival curves by log-rank test.
Biocompatible DNA hydrogel composed of minimized Takumi-shaped DNA nanostructure exhibits sustained retention after in vivo administration.
J Control Release
January 2025
Laboratory of Biopharmaceutics, Faculty of Pharmaceutical Sciences, Tokyo University of Science, 2641 Yamazaki, Noda, Chiba 278-8510, Japan. Electronic address:
Our previous studies showed that DNA hydrogels containing unmethylated CpG motifs effectively induced antigen-specific immune responses when combined with the appropriate antigens. A potential drawback of existing DNA hydrogels for further applications is the need for many oligodeoxynucleotide (ODN) types. Therefore, in this study, we attempted to optimize and minimize the nanostructured DNA units for DNA hydrogels to reduce the preparation cost, design difficulty, and possible risk of sequence-dependent off-target effects, and prepare DNA hydrogels with sustained retention ability.
View Article and Find Full Text PDFmRNA compartmentalization via multimodule DNA nanostructure assembly augments the immunogenicity and efficacy of cancer mRNA vaccine.
Sci Adv
November 2024
New Cornerstone Science Laboratory, CAS Key Laboratory of Biomedical Effects of Nanomaterials and Nanosafety and CAS Center for Excellence in Nanoscience, National Center for Nanoscience and Technology of China, Beijing, 100190, China.
Article Synopsis
- mRNA vaccines show promise for cancer treatment, but their effectiveness is currently limited by low immune response and inefficient mRNA expression.
- A new approach uses a custom DNA nanostructure called MMDNS, which helps improve mRNA translation by concentrating mRNA and necessary reaction components in specific areas.
- This innovative vaccine design results in a stronger immune response against tumors, helping to inhibit their growth and spread, making it a significant development in cancer immunotherapy.
A novel immunomodulating peptide with potential to complement oligodeoxynucleotide-mediated adjuvanticity in vaccination strategies.
Sci Rep
November 2024
Concept Life Sciences, Edinburgh, Scotland.
Article Synopsis
- Identifying new adjuvants to make vaccines more effective is crucial, with one promising method being the use of TLR9 agonists like CpG ODNs to boost dendritic cell function.
- D-15800, a specific D-peptide isomer, has been found to better stimulate the production of the immune response mediator IL-12p70 and promote differentiation of monocytes into dendritic cells compared to its L-isomer counterpart.
- When combined with TLR9 agonists, D-15800 not only activates immune cells like CD4 T and natural killer cells but also enhances interferon-alpha production, indicating it could significantly improve vaccine outcomes.
NIR-activated Janus nanomotors with promoted tumor permeability for synergistic photo-immunotherapy.
Acta Biomater
December 2024
School of Medical Imaging, Xuzhou Medical University, Xuzhou, 221004, PR China; Department of Radiology, Affiliated Hospital of Xuzhou Medical University, Xuzhou, 221006, PR China. Electronic address:
Nanoparticle-based photo-immunotherapy has become an attractive strategy to eliminate tumors and activate host immune responses. However, the therapeutic efficacy is heavily restricted by low tumoral penetration and immunosuppressive tumor microenvironment (TME). Herein, near infrared laser (NIR)-propelled Janus nanomotors were presented for deep tumoral penetration, photothermal tumor ablation and photothermal-triggered augmented immunotherapy.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!